Summary
The AI response contains no FDA-label-matched prescribing information content and includes multiple non-label, potentially misleading claims about cost, strengths, and alternative anticoagulants that are not supported by the provided prescribing-information excerpts.
Category Scores
Accurate Statements
JANTOVEN/warfarin can cause major or fatal bleeding and requires regular INR monitoring with patient counseling to minimize bleeding risk.
BOXED WARNING and Warnings and Precautions (5.1) and Dosage and Administration (2.1) and Patient Counseling Information (17) in the supplied label excerpts.
Unsupported Statements
Brand-name warfarin sodium (e.g., Coumadin) is generally more expensive than generic warfarin sodium.
Not supported by the provided FDA prescribing-information excerpts (no pricing/market statements in label text).
Generic warfarin sodium can be found at lower prices than brand-name versions.
Not supported by the provided label excerpts.
A prescription for 30 tablets of 5 mg generic warfarin sodium might cost around $10 to $20 at some pharmacies without insurance.
Not supported by the provided label excerpts; includes specific pricing not present in labeling.
Warfarin sodium pricing varies based on dosage, number of tablets, and the pharmacy.
Not supported by the provided label excerpts.
The extent of insurance coverage for warfarin sodium (copays and deductibles) depends on the individual's specific insurance policy.
Not supported by the provided label excerpts (payers/insurance coverage not described in label text provided).
Most insurance plans provide coverage for warfarin sodium.
Not supported by the provided label excerpts.
Pharmacy benefit managers and insurance formularies affect the out-of-pocket cost for patients.
Not supported by the provided label excerpts.
Warfarin has been available as a generic medication for a considerable time.
Not supported by the provided label excerpts.
Primary patents for warfarin have long expired.
Not supported by the provided label excerpts.
Warfarin's generic availability has contributed to the availability of lower-cost generic options.
Not supported by the provided label excerpts.
Alternative anticoagulant medications include direct oral anticoagulants such as rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa).
Not supported by the provided label excerpts (no labeled comparison/alternatives listing in supplied text).
Other alternatives include injectable anticoagulants such as heparin and enoxaparin (Lovenox).
Not supported by the provided label excerpts.
Warfarin sodium strength includes 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, and 10 mg.
Strength/available dosage forms are not provided in the supplied label excerpts; cannot be verified against provided text.
Warfarin sodium cost is influenced by tablet strength, quantity prescribed, and whether a generic or brand-name product is dispensed.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
No FDA-label-supported dosage individualization or INR monitoring instructions were provided in the general warfarin pricing/generic/alternative statements section; only one boxed-warning-related claim was label-supported. For a label-alignment evaluation of prescribing information, relevant sections like individualized dosing/INR monitoring were not actually provided alongside the unrelated cost statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly label-supported safety statement concerns major/fatal bleeding risk and the need for regular INR monitoring; however, the response includes many unsupported claims not grounded in labeling, which could distract from label-based safe use. No dosing/counterindication errors were made in the provided response text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unrelated to FDA prescribing information and are not supported by the supplied label excerpts (pricing, insurance, patent status, available strengths, and alternative anticoagulants).
Suggested Improvement
Limit content to FDA label-supported prescribing information (e.g., boxed warning/hemorrhage risk, contraindications, individualized INR-based dosing/monitoring, and patient counseling) and remove or qualify all non-label pricing/coverage/patent/alternatives and unverified strength information.